






Post MI Prevalence: 2024 female Baseline 0.06 Lifestyle Outreach 0.05 Polypill 0.04 0.03 0.02 0.01 0.00 95\_plus -40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 90\_to\_94 30\_to\_34 35\_to\_39 50\_to\_54 55\_to\_59 60\_to\_64 85\_to\_89 25\_to\_29 65\_to\_69 80\_to\_84












Post MI Prevalence: 2030 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 55\_to\_59 60\_to\_64 80\_to\_84 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 50\_to\_54 65\_to\_69

Post MI Prevalence: 2031 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 -0.04 0.03 0.02 0.01 0.00 40\_to\_44 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 65\_to\_69



Post MI Prevalence: 2033 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 -0.03 0.02 0.01 0.00 40\_to\_44 70\_to\_74 75\_to\_79 30\_to\_34 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 85\_to\_89 90\_to\_94 95\_plus 25\_to\_29 35\_to\_39 65\_to\_69

Post MI Prevalence: 2034 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 55\_to\_59 60\_to\_64 80\_to\_84 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 50\_to\_54 65\_to\_69

Post MI Prevalence: 2035 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 50\_to\_54 65\_to\_69 80\_to\_84


Post MI Prevalence: 2036 female Baseline 0.07 Lifestyle Outreach 0.06 Polypill 0.05 0.04 0.03 0.02 0.01 0.00 70\_to\_74 · 40\_to\_44 75\_to\_79 30\_to\_34 45\_to\_49 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 95\_plus 25\_to\_29 35\_to\_39 50\_to\_54 65\_to\_69 80\_to\_84


Post MI Prevalence: 2037 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 50\_to\_54 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 65\_to\_69 80\_to\_84


Post MI Prevalence: 2038 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 50\_to\_54 65\_to\_69 80\_to\_84


Post MI Prevalence: 2039 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 -0.03 0.02 0.01 0.00 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 50\_to\_54 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 25\_to\_29 35\_to\_39 65\_to\_69 80\_to\_84


Post MI Prevalence: 2040 female 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 -0.03 0.02 0.01 40\_to\_44 45\_to\_49 70\_to\_74 75\_to\_79 95\_plus 30\_to\_34 35\_to\_39 55\_to\_59 60\_to\_64 85\_to\_89 90\_to\_94 25\_to\_29 50\_to\_54 65\_to\_69 80\_to\_84












































Post MI Prevalence: 2039 male Baseline 0.12 Lifestyle Outreach 0.10 Polypill 0.08 0.06 0.04 0.02 0.00 95\_plus -40\_to\_44 75\_to\_79 90\_to\_94 30\_to\_34 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 65\_to\_69 70\_to\_74 85\_to\_89 25\_to\_29 35\_to\_39 80\_to\_84

